PRODUCT DATA SHEET



Bioworld Technology CO., Ltd.

EGFR (F1065) Peptide

Cat No.: BS1795P

Background

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Ligand binding promotes the internalization of EGFR via Clathrin-coated pits and its subsequent degradation in response to its intrinsic tyrosine kinase. EGFR is involved in organ morphogenesis and maintenance and repair of tissues, but upregulation of EGFR is associated with tumor progression. The oncogenic effects of EGFR include initiation of DNA synthesis, enhanced cell growth, invasion and metastasis. Abrogation of EGFR results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells, suggesting that EGFR may be an effective therapeutic target.

Swiss-Prot

P00533

Applications

Blocking

Specificity

This peptide can be used with studies using BS1795 EGFR (F1065) pAb.

Purification & Purity

Synthetic peptide EGFR (F1065). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at $4\,\mathrm{C}$ short term. Aliquot and store at -20 C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.